Ratings Aveanna Healthcare Holdings Inc.

Equities

AVAH

US05356F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.31 ^USD	+1.76%		+4.05%	-13.81%

Apr. 03	Aveanna Healthcare Holdings Inc Announces Appointment of Jerry Perchik to Serve as Chief Legal Officer and Secretary, Effective April 29, 2024	CI
Mar. 18	Deutsche Bank Adjusts Aveanna Healthcare Price Target to $3 From $2, Maintains Buy Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
For the past twelve months, EPS forecast has been revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AVEANNA HEALTHCARE HOLDINGS INC.	-13.81%	444M		D+
CVS HEALTH CORPORATION	-14.17%	85.42B		B-
HCA HEALTHCARE, INC.	+17.86%	84.38B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.39B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.51%	17.49B		B
FRESENIUS SE & CO. KGAA	-2.28%	16.44B		A-
QUEST DIAGNOSTICS INCORPORATED	-0.24%	15.28B		A-
FRESENIUS MEDICAL CARE AG	+0.74%	12.22B		A-
PURE HEALTH HOLDING	-31.23%	11.98B	-	-
EUROFINS SCIENTIFIC SE	-2.98%	11.71B		A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes